Christopher O’Reilly | Global Head, IR & Global Finance |
Christophe Weber | President and CEO |
Andy Plump | President Research and Development |
Costa Saroukos | CFO |
Masato Iwasaki | Japan General Affairs |
Ramona Sequeira | President, U.S. Business Unit and Global Portfolio Commercialization |
Julie Kim | President, Plasma-Derived Therapies Business Unit |
Hidemaru Yamaguchi | Citi |
Kazuaki Hashiguchi | Daiwa Securities |
Akinori Ueda | Goldman Sachs |
Steve Barker | Jefferies |
Seiji Wakao | JP Morgan |
Fumiyoshi Sakai | Credit Suisse |
Shinichiro Muraoka | Morgan Stanley |
Before starting, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on page 2 of the presentation.
So, from our side, as presenters and also the panel, we have President and CEO, Christophe Weber; and Andy Plump, President Research and Development; Costa Saroukos, Chief Financial Officer; and Masato Iwasaki, Japan General Affairs; and Ramona Sequeira, President of U.S.